Introduction: OVA is not required for DO11.10 derived Treg cell inhibition of colitis induced by Balb/c CD45RBhi T cells. Transferred DO11.10 CD25+ cells proliferate in vivo in the absence of cognate antigen. This suggests that either DO11.10 Treg cells recognize other antigens via a second TCR or function independent of TCR stimulation. Methods: We stimulated DO11.10 CD4+CD25-T cells to proliferate with OVA pulsed APC. Increasing numbers of Balb/c, which do not recognize OVA, or DO11.10 CD4+CD25+ Treg were added to these cultures. In addition, we tested if DO11.10 CD4+CD25+ Treg were able to inhibit SEA induced proliferation of Balb/c T effector cells. SEA stimulates Vbeta 3,6 and 11 found on Balb/c but is not found on DO11.10 T cells which only express Vbeta8. Results: BALB/c CD25+ Treg suppressed the OVA induced proliferation of DO11.10 CD25-. DO11.10 CD25+ Treg cells suppressed SEA induced proliferation of Balb/c effector cells in a dose dependent fashion. Conclusion: These results indicate that cognate antigen is not required for Treg cells to suppress antigen induced T cell proliferation in vitro. We conclude that Treg cell function is antigen independent or once activated suppress other Ag responses in a non-specific bystander fashion.
Being endowed with immunosuppressive activity, regulatory T cells (Treg) are regarded as an alternative target for the treatment of autoimmunity. Notably, the capacity of Tregs to suppress depends on Treg migration into the inflamed tissue. In an attempt to improve Treg-based therapeutic strategies, we tested whether priming Tregs in vitro to migrate to mucosal tissues would enhance their efficacy to suppress intestinal inflammations. Using retinoic acid (RA), gut-specific homing molecules α4β7 and CCR9 were induced on in vitro expanded Tregs. In fact, RA-treated Tregs were more potent suppressors of an acute intestinal inflammation compared with control Tregs. Conversely, the efficacy of Tregs to resolve an established chronic inflammation of the colon was not affected by RA-treatment. The latter finding was associated with a rapid decrease of RAinduced α4β7 expression and de novo induction of homing Foxp3 expression has generally been believed to represent an essential molecule to determine the regulatory ability of CD4(+) T cells. We herein describe a unique CD4(+)CD25(high) T cell population (termed exCD25 T cells) that can be generated ex vivo in the presence of high dose of IL-2. The exCD25 T cells possess regulatory abilities to suppress naïve T cell proliferation in vitro and inhibit the CD45RB(high) T cell-induced colitis in vivo even in absence of Foxp3 expression. The exCD25 T cells without Foxp3 expression retain some phenotypic characteristics with typical Foxp3(+) Treg (e.g. highly expressed CD25 and GITR) but lack expression of CTLA4 that is required for the function of Foxp3(+) Treg. In addition, similar to Foxp3(+) Treg, chromatin remodeling within the promoter region of the IL-2 locus remains impaired in exCD25 T cells. Of note, in contrast to Foxp3(+) Treg, exCD25 T cells have a potential ability to induce colitis and hepatitis. The dual roles (regulatory versus pathogenic) are determined by paracrine IL-2 supplied from non-CD4(+) T cells such as TCR gamma/delta T cells. These finding suggest a Foxp3-independent immune regulatory function that can be reversed depending on paracrine IL-2. The lack of P-glycoprotein (P-gp), encoded by the multidrug resistance gene (mdr1a), in FVB.mdr1a -/-mice results in T cell mediated colitis. We hypothesize a defect in CD4 + CD25 + Foxp3 + regulatory T cell (T reg ) function is resulting in colitis in these animals. To examine the regulatory capacity of P-gp deficient T reg , CD4 + CD25 -T effector cells (T eff ) and CD4 + CD25 + T reg from FVB.mdr1a -/-mice were cultured together utilizing anti-CD3 stimulation. Proliferation of T cells was then measured by 3 H-Thymidine incorporation. P-gp deficient T reg displayed similar suppressive ability as wild type FVB control T reg . To test FVB.mdr1a -/-T reg function in vivo, T reg and T eff isolated from FVB or FVB.mdr1a -/-mice were adoptively transferred into FVB.rag -/-. Recipients were monitored for colitis development, as measured by weight loss, diarrhea, or rectal prolapse. Initial weight changes indicate FVB and FVB.mdr1a -/-T reg protect from colitis. Both the in vitro cell culture studies and in vivo adoptive transfer experiments suggest that there is no innate defect in P-gp deficient T reg suppressive activity. Because P-gp is required for dendritic cell (DC) differentiation, and DCs are vital to successful T reg activation, the defect may be in DC/T reg interaction. Support: HHMI Med-to-Grad Fellowship, CCFA Student Fellowship Award, NIH P01 DK071176, UAB Digestive Diseases Research Development Center #P30 DK064400. Oral tolerance is associated with regulatory T-cell (Tr) induction in the mesenteric lymph nodes (MLN). T cells in MLN differentially express the ectoenzyme CD38 whereas the molecule is not expressed during a non-mucosal response. We determined the role of CD38 in mucosal T cell responses and its potential to identify mucosal T cells within the systemic T cell pool. CD38 expression was induced on T cells after co-culture with MLN-DC and TGF-β. Treatment with retinoic acid (RA) receptor-antagonists revealed that endogenous RA production by MLN-DC stimulated CD38 induction. As TGF-β and RA induce mucosal Foxp3+ Tr differentiation we assessed whether CD38 is selectively expressed on Foxp3+ cells. However, when Foxp3+ Tr differentiation was blocked, CD38 expression was maintained. This implies that CD38 expression on T cells reflects mucosal imprinting irrespective of effector or regulatory function. To establish that CD38 identifies mucosal T cells in peripheral blood, CD62L-CD38+ T cells from healthy individuals were analyzed. CD62L-CD38+ T cells selectively expressed the guthoming receptor CCR9 and preliminary data show the subset expressed high levels of the cytokine IL-10. In conclusion, CD38 expression identifies T cells that have been imprinted by encounter with mucosal DC. This restricted population may reflect ongoing intestinal immune responses and provide insights into the pathogenesis of intestinal disease. Gut mucusa parameters may play an important role in mediating the effects of environmental factors on development of type 1 diabetes (T1D). In this study we investigated intestinal permeability, gut maturation (activities of brush border enzymes) and lymphocyte subsets within the gut mucosa of NOD vs. BALB/c female mice. In addition, mucosal lymphocytes were also evaluated in NOD mice fed diabetes-preventive, gluten-free Altromin diet. Significantly decreased intestine permeability, measured as urine lactulose/rhamnose ratio, was found in NOD compared to BALB/c mice. Increased lactase and decreased sucrase activities were found in jejuna of NOD vs. BALB/c mice. Alkaline phosphatase values were substantially increased in NOD mice. No significant changes were observed in jejunal activities of DPP IV, glucoamylase and γ-glutamyltransferase. Using immunohistochemistry, significantly lower numbers of CD3+ , CD8+α, T-γδ+ cells and IgA+ but not IgM+ and CD4+ were observed in proximal and distal jejunum as well as ileum of NOD mice compared to BALB/c mice. Furthermore, a significantly lower ratio of intraepithelial to lamina propria CD3+ cells was found in NOD mice. Interestingly, NOD mice fed gluten-free diet displayed lower number of CD3+ cells with the lamina propria compartment. Altered villus architecture was documented in jejuna of NOD vs. BALB/c female mice. Our results showed a decreased intestine permeability, immature-activated enzyme profile of the small intestine, and an impairment of gut mucosal immune system of pre-diabetic NOD compared to BALB/c mice as well as changes in lamina propria T cells in NOD mice on gluten-free diet. The impairment of gut mucosa in NOD mice may contribute to autoimmunity, e.g. by failing to shape the proper mucosal regulatory immune response to outer environmental stimuli. Type 2 diabetes is characterized by increased blood glucose, and insulin resistance. The etiology of type 2 diabetes involves immune mediated metabolic dysregulation and characterized by inflammatory signaling, monocyte infiltration in adipose tissue and a lack of glucose regulation. We have previously shown that oral anti-CD3 suppresses EAE, lupus and type 1 diabetes by generating inducible CD4+LAP+ regulatory T cells. Administration of GC shows a marked reduction in hepatic fat content and improved glucose tolerance. We hypothesized that immune regulation by oral anti-CD3/GC may impact disease in the OB/ OB mouse. We found that oral anti-CD3/GC decreased pancreatic islet cell hyperplasia and decreased accumulation of fat in the liver as well as lowered blood glucose and liver enzymes. In adoptive transfer studies these effects were shown to be mediated by CD4+LAP+ Tregs in a TGF-beta dependent manner. In addition, we found that treatment decreased the expression of inflammatory cytokines (IL-1B, TNF, IL-6) by adipocytes and the number of macrophages in white fat. There is also a marked decrease in production of inflammatory cytokines by splenocytes. These findings demonstrate the involvement of inflammatory immune mechanisms in type 2 diabetes and oral anti-CD3/GC treatment suppressed these mechanisms and improved disease.
